Korro to Participate in Upcoming Investor Conferences
01 April 2024 - 10:01PM
Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief
Executive Officer and President, Ram Aiyar, Ph.D., Chief Financial
Officer, Vineet Agarwal, and Chief Scientific Officer, Steve
Colletti, Ph.D., will participate, present, and meet investors
regarding progress of KRRO-110, Korro’s best-in-class candidate for
AATD, at the following upcoming investor conferences:
23rd Annual Needham
Healthcare ConferenceFormat:
PresentationDate and Time: Monday, April 8, 2024,
1:30 p.m. ET
Piper Sandler Spring
Biopharma Symposium Date: Tuesday, April
16, 2024
Citizens JMP Life Sciences
ConferenceFormat:
PresentationDate and Time: Monday, May 13, 2024,
12:30 p.m. ET
2024 RBC Capital Markets
Global Healthcare Conference Format:
PresentationDate and Time: Tuesday, May 14, 2024,
10:00 a.m. ET
Bank of America Securities
Health Care Conference 2024Format:
PresentationDate and Time: Wednesday, May 15,
2024, 11:15 a.m. ET
The live webcasts of the presentations can be
accessed on the "Events & Presentations" page in the Investor
section of Korro’s website at www.korrobio.com. Following the
presentation, a replay of the event will be available for 30
days.About Korro
Korro is a biopharmaceutical company focused on
developing a new class of genetic medicines for both rare and
highly prevalent diseases using its proprietary RNA editing
platform. Korro is generating a portfolio of differentiated
programs that are designed to harness the body’s natural RNA
editing process to effect a precise yet transient single base edit.
By editing RNA instead of DNA, Korro is expanding the reach of
genetic medicines by delivering additional precision and
tunability, which has the potential for increased specificity and
improved long-term tolerability. Using an oligonucleotide-based
approach, Korro expects to bring its medicines to patients by
leveraging its proprietary platform with precedented delivery
modalities, manufacturing know-how, and established regulatory
pathways of approved oligonucleotide drugs. Korro is based in
Cambridge, Mass. For more information, visit korrobio.com.
Korro Contact Information
InvestorsIR@korrobio.com
MediaGlenn Silver FINN
Partners Glenn.silver@finnpartners.com
Korro Bio (NASDAQ:KRRO)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Korro Bio (NASDAQ:KRRO)
Historical Stock Chart
Von Jun 2023 bis Jun 2024